Figure Legends for Supplementary Figures from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Yan Kong,Lu Si,Yiqian Li,Xiaowen Wu,Xiaowei Xu,Jie Dai,Huan Tang,Meng Ma,Zhihong Chi,Xinan Sheng,Chuanliang Cui,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22461800.v1

2023-01-01

Abstract:Figure legends for Supplementary Figure S1 and Figure S2

What problem does this paper attempt to address?

Supplementary Figure Legends from Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells

Rajat Bhattacharya,Xiang-Cang Ye,Rui Wang,Xia Ling,Madonna McManus,Fan,Delphine Boulbes,Lee M. Ellis

DOI: https://doi.org/10.1158/0008-5472.22407995.v1

2023-01-01

Abstract:Legends for Supplementary Figures S1-S12.
Supplementary Figure S1 from Analysis of mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Yan Kong,Lu Si,Yiqian Li,Xianliang Wu,Xiaowei Xu,Jie Dai,Huan Tang,Meng Ma,Zhihong Chen,Xinan Sheng,Chuanliang Cui,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22461797.v1

2023-01-01

Abstract:Supplementary Figure S1. Typical staining results of immunohistochemistry.
Supplementary Figure S2 from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Yan Kong,Lu Si,Yiqian Li,Xiaowen Wu,Xiaowei Xu,Jie Dai,Huan Tang,Meng Ma,Zhihong Chi,Xinan Sheng,Chuanliang Cui,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22461794

2023-01-01

Abstract:Supplementary Figure S2. Overall survival of melanoma patients in relation to mTOR nonsynonymous mutations.
Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Jiahui Mou,Meijun Huang,Feifei Wang,Xiaoding Xu,Hanqi Xie,Henglei Lu,Mingyang Li,Yu Li,Weiwen Kong,Jing Chen,Ying Xiao,Yiding Chen,Chaochen Wang,Jin Ren

DOI: https://doi.org/10.1158/1541-7786.22527890

2023-01-01

Abstract:Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis
Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Junying Zeng,Sharad Sharma,Yong‐Qing Zhou,Hang‐Ping Yao,Xing Hu,Ruiwen Zhang,Ming-Hai Wang

DOI: https://doi.org/10.1158/1535-7163.22503690

2023-01-01

Abstract:PDF - 71K, Legends for Supplementary Figures 1 through 5.
Supplementary Table S6 from Analysis of mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Yan Kong,Lu Si,Yiqian Li,Xianliang Wu,Xiaowei Xu,Jie Dai,Huan Tang,Meng Ma,Zhihong Chen,Xinan Sheng,Chuanliang Cui,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22461785

2023-01-01

Abstract:Supplementary Table S6. Statistical analysis of the effects of PI3K-AKT-mTOR inhibitors on proliferation of HEK293T cells bearing mTOR mutation.
Supplementary Figure Legends from Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer

Li Liu,Xue Bai,Jian Wang,Xiaonan Tang,Dehua Wu,Shasha Du,Xiu-Ju Du,Yao-Wei Zhang,Hai‐Liang Zhu,Yuan Fang,Zhimou Guo,Qiandong Zeng,Xuejun Guo,Zhu Li,Zhong‐Yi Dong

DOI: https://doi.org/10.1158/1078-0432.22471917.v1

2023-01-01

Abstract:Supplementary figure legends
Supplementary Figure Legends 1-6, Methods from Pivotal Role of Reduced let-7g Expression in Breast Cancer Invasion and Metastasis

Pengxu Qian,Zehua Zuo,Zhengsheng Wu,Xianyi Meng,Gaopeng Li,Zhengzhou Wu,Weijie Zhang,Sheng Tan,Vijay Pandey,Yandan Yao,Puyue Wang,Liqing Zhao,Jun Wang,Qiang Wu,Erwei Song,Peter E. Lobie,Zhinan Yin,Tao Zhu

DOI: https://doi.org/10.1158/0008-5472.22391054

2023-01-01

Abstract:PDF file - 214K
Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Jeff Hsu,Colin Chong,Jeffrey Serrill,Levina Goon,Joan Balayan,Eric N. Johnson,Grachelle Lorenzana,Sharon Wu,Kevin G. Leong,Theodore J. Yun,Yong Wang,Faming Jiang,Lynne Bannen,Peter Lamb,Wei Xu,Peiwen Yu

DOI: https://doi.org/10.1158/1535-7163.22523460

2023-01-01

Abstract:Supplementary Figures and Tables with adjoining Legends
Supplementary Figure 3 from Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Jie Dai,Yan Kong,Lu Si,Zhihong Chi,Chuanliang Cui,Xinan Sheng,Lili Mao,Siming Li,Bin Lian,Ruifeng Yang,Shujing Liu,Xiaowei Xu,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22446036.v1

2023-01-01

Abstract:PDF file - 2243K, Figure S3. Genetic mutations in exon 18 of PDGFRA.
Supplementary Figure 3 from Large-scale Analysis of pdgfra Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Jie Dai,Yan Kong,Lu Si,Zhihong Chen,Chuanliang Cui,Xinan Sheng,Lili Mao,Siming Li,Bin Lian,Ruijin Yang,Shujing Liu,Xiaowei Xu,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22446036

2023-01-01

Abstract:PDF file - 2243K, Figure S3. Genetic mutations in exon 18 of PDGFRA.
Supplemental Figure Legends from Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma

Jenifer B. Gifford,Wei Huang,Ann E. Zeleniak,Antreas Hindoyan,Hong Wu,Timothy R. Donahue,Reginald Hill

DOI: https://doi.org/10.1158/1535-7163.22508517

2023-01-01

Abstract:Figure legends for the supplemental table and each of the supplemental figures.
Supplementary Figure 2 from Large-scale Analysis of pdgfra Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Jie Dai,Yan Kong,Lu Si,Zhihong Chen,Chuanliang Cui,Xinan Sheng,Lili Mao,Siming Li,Bin Lian,Ruijin Yang,Shujing Liu,Xiaowei Xu,Jun Guo

DOI: https://doi.org/10.1158/1078-0432.22446039

2023-01-01

Abstract:PDF file - 1452K, Figure S2. Genetic mutations in exon 14 of PDGFRA.
Supplementary Figure Legends 1-2 from Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma

Michael A. Davies,Patricia S. Fox,Nicholas E. Papadopoulos,Agop Y. Bedikian,Wen‐Jen Hwu,Alexander J. Lazar,Víctor G. Prieto,Kirk S. Culotta,Timothy Madden,Qiang Xu,Sha Huang,Wanleng Deng,Chaan S. Ng,Sanjay Gupta,Wenbin Liu,Janet Dancey,John Wright,Roland L. Bassett,Patrick Hwu,Kevin B. Kim

DOI: https://doi.org/10.1158/1078-0432.22444286

2023-01-01

Abstract:PDF file - 85K
Supplementary Figure Legends from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Dalong Cao,Zihao Qi,Yangyang Pang,Haoran Li,Huyang Xie,Junlong Wu,Yongqiang Huang,Yao Zhu,Yijun Shen,Yiping Zhu,Bo Dai,Xin Hu,Dingwei Ye,Ziliang Wang

DOI: https://doi.org/10.1158/0008-5472.22418970

2023-01-01

Abstract:Supplementary Figure Legends
Supplementary Figure Legend from Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2

Ninghui Mao,Dong Gao,Wenhuo Hu,Sunyana Gadal,Haley Hieronymus,Shangqian Wang,Young Sun Lee,Patrick Sullivan,Zeda Zhang,Danielle Choi,Neal Rosen,Charles L. Sawyers,Anuradha Gopalan,Yu Chen,Brett S. Carver

DOI: https://doi.org/10.1158/0008-5472.22426324.v1

2023-01-01

Abstract:Figure Legend for supplementary figures
Supplementary Figure and Table Legends from Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells

Li Lin,Brian Hutzen,Mingxin Zuo,Sarah Ball,Stephanie Deangelis,Elizabeth Foust,Bulbul Pandit,Michael A. Ihnat,Satyendra S. Shenoy,Samuel Kulp,Pui-Kai Li,Chenglong Li,James Fuchs,Jiayuh Lin

DOI: https://doi.org/10.1158/0008-5472.22387137.v1

2023-01-01

Abstract:Supplementary Figure and Table Legends from Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells
Supplementary Figures and Figure Legends from MetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR Pathway

Tao Yu,Yingjun Zhao,Zhixiang Hu,Jing Li,Dandan Chu,Jiwei Zhang,Zhe Li,Bing Chen,Xiao Zhang,Hongyu Pan,Shengli Li,Hechun Lin,Lei Liu,Mingxia Yan,Xianghuo He,Ming Yao

DOI: https://doi.org/10.1158/0008-5472.22418432.v1

2023-01-01

Abstract:Supplementary Figures and Figure legends that contain the information of the characteristics of MetaLnc9 in NSCLC, Non-coding RNA analysis, the efficiency for MetaLnc9 overexpression and Knockdown, the molecular mechanism of PGK1 and NONO.
Supplementary Figure Legends from Mir-508 Defines the Stem-like/Mesenchymal Subtype in Colorectal Cancer

Ting-Ting Yan,Lin-Lin Ren,Chao-Qin Shen,Zhen-Hua Wang,Ya-Nan Yu,Qian Liang,Jia-Yin Tang,Ying-Xuan Chen,Dan-Feng Sun,Witold Zgodzinski,Marek Majewski,Piotr Radwan,Ilona Kryczek,Ming Zhong,Jinxian Chen,Qiang Liu,Weiping Zou,Hao-Yan Chen,Jie Hong,Jing-Yuan Fang

DOI: https://doi.org/10.1158/0008-5472.22417241

2023-01-01

Abstract:This file contains figure legends corresponding to supplementary figures.

Figure Legends for Supplementary Figures from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure Legends from Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells

Supplementary Figure S1 from Analysis of <i>mtor</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure S2 from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Table S6 from Analysis of <i>mtor</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure Legends from Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer

Supplementary Figure Legends 1-6, Methods from Pivotal Role of Reduced <i>let-7g</i> Expression in Breast Cancer Invasion and Metastasis

Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Supplementary Figure 3 from Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplementary Figure 3 from Large-scale Analysis of <i>pdgfra</i> Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplemental Figure Legends from Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma

Supplementary Figure 2 from Large-scale Analysis of <i>pdgfra</i> Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplementary Figure Legends 1-2 from Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma

Supplementary Figure Legends from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Supplementary Figure Legend from Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2

Supplementary Figure and Table Legends from Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells

Supplementary Figures and Figure Legends from MetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR Pathway

Supplementary Figure Legends from Mir-508 Defines the Stem-like/Mesenchymal Subtype in Colorectal Cancer

Figure Legends for Supplementary Figures from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure Legends from Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells

Supplementary Figure S1 from Analysis of &lt;i&gt;mtor&lt;/i&gt; Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure S2 from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Table S6 from Analysis of &lt;i&gt;mtor&lt;/i&gt; Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure Legends from Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer

Supplementary Figure Legends 1-6, Methods from Pivotal Role of Reduced &lt;i&gt;let-7g&lt;/i&gt; Expression in Breast Cancer Invasion and Metastasis

Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Supplementary Figure 3 from Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplementary Figure 3 from Large-scale Analysis of &lt;i&gt;pdgfra&lt;/i&gt; Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplemental Figure Legends from Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma

Supplementary Figure 2 from Large-scale Analysis of &lt;i&gt;pdgfra&lt;/i&gt; Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplementary Figure Legends 1-2 from Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma

Supplementary Figure Legends from Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance Via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer

Supplementary Figure Legend from Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2

Supplementary Figure and Table Legends from Novel STAT3 Phosphorylation Inhibitors Exhibit Potent Growth-Suppressive Activity in Pancreatic and Breast Cancer Cells

Supplementary Figures and Figure Legends from MetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR Pathway

Supplementary Figure Legends from Mir-508 Defines the Stem-like/Mesenchymal Subtype in Colorectal Cancer

Supplementary Figure S1 from Analysis of <i>mtor</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Table S6 from Analysis of <i>mtor</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure Legends 1-6, Methods from Pivotal Role of Reduced <i>let-7g</i> Expression in Breast Cancer Invasion and Metastasis

Supplementary Figure 3 from Large-scale Analysis of <i>pdgfra</i> Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplementary Figure 2 from Large-scale Analysis of <i>pdgfra</i> Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib